PTC Therapeutics

Update in progress

PTCT (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

PTC Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for rare disorders in the United States and worldwide. It markets Translarna and Emflaza for Duchenne muscular dystrophy; Upstaza for AADC deficiency; Tegsedi and Waylivra for rare diseases; and Evrysdi for spinal muscular atrophy in adults and children. Its pipeline includes Sepiapterin, PTC518 for Huntington’s disease, and vatiquinone for Friedreich’s ataxia. It partners with Roche, Novartis, SMA Foundation, Akcea, and others, and markets Upstaza in the U.S. as Kebilidi. Based in Warren, New Jersey, established 1998.

Company score

Sentiment: -0.05; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.05; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive